【摘要】 目的：比较喹硫平与利培酮对女性精神分裂症的疗效及副作用。方法：将符合CCMD-3 精神分裂症诊断标准的67例女性患者随机分为两组，分别给予喹硫平与利培酮治疗，疗程为8周。以阳性症状和阴性症状量表(PANSS)、临床疗效总评量表﹙CGI)评定疗效、以精神药物副反应量表﹙TESS)评定副反应。 结果：治疗8周后，两组患者的PANSS、CGI评分均明显减少，差异有显著性﹙P﹤0.01)。两组间比较PANSS、CGI评分差异无显著性(P>0.05)。喹硫平组副反应发生率低于利培酮组，差异有显著性(P<0.05)。结论：喹硫平与利培酮对女性精神分裂症的疗效相当，有效率分别为81.9%、85.3%。喹硫平锥体外系副反应和内分泌改变较利培酮少，更适用于女性精神分裂症患者。

    【关键词 】 精神分裂症；喹硫平；利培酮；疗效；副作用

    Comparison of curative effect and safety of quetiapine and risperidone in the treatment of female schizophrenia

    CAO Chang-an,GUO Jin-hong, GAO huan

    (Shenzhen Kangning hospital, Shenzhen 518020, China)

    【Abstract】 Objective：To compare the curative effect and safety of the therapy scheme to apply quetiapine and risperidone to the female schizophrenia. Methods:67 female patients with schizophrenia by CCMD-3 were randomly allocated to two groups treated with quetiapine or risperidone for 8 week. We evaluate the result by the Positive and Negative Syndrome Scale for schizophrenia (PANSS), the Clinical Global Impression Scale (CGI), the Treatment Emergent Symptom Scale (TESS).Results: By the end of the 8 weeks, the PANSS and CGI scores of two groups decreased notably (P﹤0.01). There was no significant difference between the two groups(P>0.05). Incidence of adverse effects in the quetiapine group was lower than that in the risperidone group, but the differencewas not significant(P>0.05).Conclusions: The results suggest that quetiapine is as effective as risperidone for the treatment of female schizophrenia; the effective rate of the therapy scheme is 81.9% and 85.3%. The rates of extra-pyramidal symptoms and endocrine change were higher in the risperidone group than those in the quetiapine group. Quetiapine is beneficial for female schizophrenia. ......